Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of PillCam™ Colon 2 in Visualization of the Colon

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01087528
Recruitment Status : Completed
First Posted : March 16, 2010
Results First Posted : June 8, 2012
Last Update Posted : October 22, 2020
Sponsor:
Information provided by (Responsible Party):
Medtronic - MITG

Brief Summary:
To evaluate the performance of PillCam COLON 2 in regards to detection of patients with polyps where colonoscopy is considered as the gold standard reference.

Condition or disease Intervention/treatment Phase
Colonic Diseases Bowel Diseases Device: PillCam™ (Capsule Endoscopy) Colon 2 capsule Not Applicable

Detailed Description:

Standard evaluation of subjects with suspected colon diseases includes endoscopic imaging by colonoscopy and radiology testing such as: air-contrast barium enema, abdominal/pelvic CT, or virtual colonoscopy.

The Given® Diagnostic System offers an alternative approach for endoscopic visualization of the colon. Advantages of the Given® Diagnostic System include the elimination of the need for conscious sedation, the minimally invasive, painless nature of the exam, and the ability to pursue normal daily activities immediately following the procedure . Furthermore, compared to standard colonoscopy, the Given® Diagnostic System may be more readily accepted by the subjects, thereby improving subjects' willingness to undergo a diagnostic evaluation of the colon and comply with colorectal cancer screening recommendations.

The PillCam™ SB capsule (formerly M2A® Capsule) that was cleared by the FDA- in August 2001 for small bowel evaluation has been ingested to date by more than 1,000,000 people worldwide and is well accepted by patients and physicians as well as the professional societies. However, adequate visualization of the colon cannot be achieved with the standard PillCam™ SB capsule because of the anatomical and physiological properties of the colon which are significantly different than the small bowel. Moreover, other issues that limit the evaluation of the colonic mucosa by the standard PillCam™ SB procedure include an unsatisfactory level of colon cleanliness and slow progression of the PillCam™ SB capsule through the colon during the desired examination time. Therefore, the development and introduction of a specially designed, customized colon capsule combined with a dedicated capsule colonoscopy procedure protocol will allow for more efficient evaluation of the colonic mucosa. This is expected to improve the capability of the Given® Diagnostic System to detect colonic pathologies and to serve as a diagnostic and screening tool for colonic disease. To date, several clinical studies have been conducted with Given® Diagnostic System and the PillCam™ Colon 1 capsule A pilot multicenter study is currently being conducted with a new Given® Diagnostic System and an advanced generation of the the PillCam™ Colon capsule - PillCam™ Colon 2. Capsule. The new development of Given® Diagnostic System and PillCam™ Colon 2 capsule is primarily aimed to increase sensitivity and specificity for polyp detection.

Further details of the Given® Diagnostic System and PillCam™ Colon 2 capsule can be found in the device description section.

This study is designed to evaluate the performance of the new version of Given® Diagnostic System and PillCam™ Colon 2 capsule in detecting patients with polyps and other colonic lesions as compared to conventional colonoscopy.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 51 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Evaluation of PillCam™ Colon 2 in Visualization of the Colon
Actual Study Start Date : July 2009
Actual Primary Completion Date : May 2010
Actual Study Completion Date : May 2010

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: 1
Subjects that are indicated for colonoscopy, who are suspected or known to suffer from large bowel diseases.
Device: PillCam™ (Capsule Endoscopy) Colon 2 capsule
Medical Device




Primary Outcome Measures :
  1. Accuracy of Detection in Patients With Colonic Polyps - Sensitivity [ Time Frame: within 7 days ]
    The accuracy parameters (i.e. sensitivity) were evaluated for detection of patients with polyps equal or larger than 6 mm and for detection of patients with polyps equal or larger than 10 mm by constructing 2X2 matrix (i.e. PCCE-2 performance versus the standard colonoscopy), where sensitivity and specificity, are presented with 95% Cl based on the binomial distribution. Standard colonoscopy is considered the gold standard.

  2. Accuracy of Detection in Patients With Colonic Polyps - Specificity [ Time Frame: within 7 days ]
    The accuracy parameters (i.e. specificity) were evaluated for detection of patients with polyps equal or larger than 6 mm and for detection of patients with polyps equal or larger than 10 mm by constructing 2X2 matrix (i.e. PCCE-2 performance versus the standard colonoscopy), where sensitivity and specificity, are presented with 95% Cl based on the binomial distribution. Standard colonoscopy is considered the gold standard.


Secondary Outcome Measures :
  1. Diagnostic Yield of PillCam™ COLON 2 in Detecting Colonic Lesions [ Time Frame: within 7 days ]
    The diagnostic yield (%) of PCCE-2 and colonoscopy in visualizing a variety of colonic lesion excluding polyps (e.g. inflammation, diverticulosis and bleeding lesions) is provided.

  2. Percent of Participants With Scoring Index 3 or 4 (Good or Excellent) [ Time Frame: within 7 days ]

    Overall colon cleanliness was judged for capsule endoscopy and colonoscopy on a four-point grading index scale as follows:

    1. poor cleansing level (Large amount of fecal residue.)
    2. fair cleansing level (Enough feces or dark fluid present to preclude a completely reliable examination.)
    3. good cleansing level (Small amount of feces or dark fluid, but not enough to interfere with examination.)
    4. excellent cleansing level (No more than small bits of adherent feces.)

  3. Capsule Excretion Time [ Time Frame: within 7 days ]

    Capsule excretion time is defined as the duration of ingestion to capsule excretion time. The distribution of excretion times were categorized as follows:

    • capsule excreted within 4 hours
    • capsule excreted within 6 hours
    • capsule excreted within 8 hours
    • capsule excreted 8 hours and above



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  • Subject is between the ages of 18-70
  • Subject was referred to colonoscopy for at least one of the following reasons:

    • Colorectal cancer screening for age ≥60
    • Clinical symptoms such as: rectal bleeding, hematochezia, melena, positive FOBT, recent change of bowel habits for age ≥50
    • Positive findings in the colon (e.g. Polyp ≥10mm)
    • Personal history of significant polyps( ≥6mm )that were removed at least 3 years ago (3 years and above)

Exclusion criteria

  • Age > 70 years
  • Subject has dysphagia or any swallowing disorder
  • Subject has congestive heart failure
  • Subject has known renal disease
  • Subject is not eligible for colon preparation due to the presence of underlying conditions based on the clinical judgment of the investigator
  • Subject has any allergy or other known contraindication to the medications used in the study
  • Subject has had prior abdominal surgery of the gastrointestinal tract other than uncomplicated procedures that would be unlikely to lead to bowel obstruction based on the clinical judgment of the investigator
  • Subject has a cardiac pacemaker or other implanted electro medical device.
  • Subject is expected to undergo MRI examination within 7 days after ingestion of the capsule.
  • Subject with any condition believed to have an increased risk for capsule retention such as Crohn's disease, intestinal tumors, radiation enteritis, incomplete colonoscopies due to obstructions or NSAID enteropathy,
  • Subject with gastrointestinal motility disorders
  • Subject has known delayed gastric emptying
  • Subject has any condition, which precludes compliance with study and/or device instructions.
  • Women who are either pregnant at the time of screening, or are of child-bearing potential and do not practice medically acceptable methods of contraception.
  • Subject suffers from life threatening conditions
  • Subject currently participating in another clinical study
  • Age>70

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01087528


Locations
Layout table for location information
United States, Indiana
Indiana University Medical Center
Indianapolis, Indiana, United States, 46202
United States, North Carolina
University of North Carolina
Chapel Hill, North Carolina, United States, 27599
United States, Ohio
Digestive Care, Inc.
Beavercreek, Ohio, United States, 45440
United States, Virginia
Gastroenterology Associates of Tidewater
Chesapeake, Virginia, United States, 23320
Sponsors and Collaborators
Medtronic - MITG
Investigators
Layout table for investigator information
Principal Investigator: Douglas Rex, Dr. Division of Gastroenterology, Indiana University Medical Center
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Medtronic - MITG
ClinicalTrials.gov Identifier: NCT01087528    
Other Study ID Numbers: MA-202
First Posted: March 16, 2010    Key Record Dates
Results First Posted: June 8, 2012
Last Update Posted: October 22, 2020
Last Verified: September 2020
Keywords provided by Medtronic - MITG:
Colonic Diseases
bowel diseases
large bowel diseases
Additional relevant MeSH terms:
Layout table for MeSH terms
Intestinal Diseases
Colonic Diseases
Gastrointestinal Diseases
Digestive System Diseases